Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials DOI Creative Commons
Lorenzo Moccia, Francesca Bardi, Maria Benedetta Anesini

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(3), P. 540 - 540

Published: Feb. 21, 2025

Background/Objectives: While positive symptoms of schizophrenia are often satisfactorily controlled, negative difficult to treat, persisting despite treatment. Different strategies have been devised deal with this problem. We aimed review drug treatment for in controlled trials marketed drugs. Methods: searched the PubMed database and resulting records’ reference lists identify eligible using schizophrenia[ti] AND “negative symptom*”[ti] as a search strategy. determined eligibility through Delphi rounds among all authors. Results: On 11 February 2025, we identified 1485 records on 3 more from lists. Eligible were 95 records. Most studies double-blind, randomized trials, carried-out add-on patients stabilized antipsychotics. Other antipsychotics most frequent comparators, followed by antidepressants, recently, antioxidants gaining importance trials. Many especially those conducted Western world, found no significant effects compared placebo, while Iranian positive, although not strong effect size. Conclusions: Current research has contributed little progress schizophrenia. The reason might reside absence knowledge mechanisms whereby these generated, which prevents us designing possibly effective strategies, and/or chronicity symptoms, they first be established even when do become fully apparent.

Language: Английский

Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials DOI Creative Commons
Lorenzo Moccia, Francesca Bardi, Maria Benedetta Anesini

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(3), P. 540 - 540

Published: Feb. 21, 2025

Background/Objectives: While positive symptoms of schizophrenia are often satisfactorily controlled, negative difficult to treat, persisting despite treatment. Different strategies have been devised deal with this problem. We aimed review drug treatment for in controlled trials marketed drugs. Methods: searched the PubMed database and resulting records’ reference lists identify eligible using schizophrenia[ti] AND “negative symptom*”[ti] as a search strategy. determined eligibility through Delphi rounds among all authors. Results: On 11 February 2025, we identified 1485 records on 3 more from lists. Eligible were 95 records. Most studies double-blind, randomized trials, carried-out add-on patients stabilized antipsychotics. Other antipsychotics most frequent comparators, followed by antidepressants, recently, antioxidants gaining importance trials. Many especially those conducted Western world, found no significant effects compared placebo, while Iranian positive, although not strong effect size. Conclusions: Current research has contributed little progress schizophrenia. The reason might reside absence knowledge mechanisms whereby these generated, which prevents us designing possibly effective strategies, and/or chronicity symptoms, they first be established even when do become fully apparent.

Language: Английский

Citations

0